Facebook
Twitter
LinkedIn
Forward
20171 WEBCAST: Evolving Strategies in the MNGMT of HSCT Associated Thrombiotic Microangiopathy
Transplant-associated thrombotic microangiopathy (TA-TMA) or hematopoietic stem cell transplant-associated TMA (HSCT-TMA) is associated with a very high rate of morbidity and mortality. Differing diagnostic criteria for syndromes that require immediate clinical management, such as TA-TMA, increases complexity in understanding these clinically important conditions. As such, transplant physicians need to be aware of all existing criteria and how they differ from each other. Conventional treatment strategies are highly inefficient; therefore, development of novel therapies that modify the activation of the complement cascade is in progress. This program will present case-based discussions that demonstrate the clinical significance of dysregulated complement activation in relation to TA-TMA, address diagnostic challenges, and incorporate new standards of patient care as new treatment options are developed and potentially introduced into the treatment paradigm.
This Community Practice Connection will feature an online series of video interviews with experts in TA-TMA, in which they review patient subpopulations that will benefit most from new agents, such as inhibitors of the complement pathway activation, and discuss the changing treatment landscape of TA-TMA. These experts will describe challenging cases of TA-TMA that they have encountered and will elaborate on how important diagnostic criteria and clinical data were integrated into the management of these patients.
This activity can be accessed using the following URL: https://www.gotoper.com/online-cme-activities/cpc/cpc-tct20hsct
Target Audience
- Hematologists
- Medical Oncologists
- Researchers
- Investigators who treat or are interested in the treatment of patients with hematologic malignancies
- Other allied healthcare professionals (Nurse Practitioners, Physician Assistants, and Nurses involved in the treatment and management of patients with hematologic malignancies
Learning Objectives
- Review current diagnostic criteria for HSCT-associated TMA and ways to differentiate it from other stem cell transplant associated complications with overlapping symptoms
- Assess the role of dysregulated complement activation in the pathogenesis of HSCT-associated TMA
- Discuss the rationale concerning the application of complement-targeted therapies, including mannan binding lectin serine peptidase 2 (MASP-2) inhibitors, in the treatment of HSCT-associated TMA
- Evaluate recent clinical trial data concerning the effectiveness of emerging therapies in the treatment of HSCT-associated TMA
Support Statement
This activity is supported by an educational grant from Omeros Corporation.
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multi-step process.
Faculty:
Samer Khaled, MD
Associate Clinical Professor
Department of Hematology & Hematopoietic Cell
Transplantation
Medical Director, Hematology/HCT Clinical Operations
Director, Hematology/HCT BMT Fellowship
City of Hope Comprehensive Cancer Center
Duarte, CA
Disclosures: Consultant: Omeros, Alexion; Speakers Bureau: Alexion.
Christopher Dandoy, MD, MSc
Assistant Professor of Clinical Pediatrics
Department of Bone Marrow Transplantation and Immune Deficiency
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
Disclosures: Christopher Dandoy, MD, MSc, has no commercial interest to disclose.
Sergio Giralt, MD
Professor of Medicine
Melvin Berlin Family Chair in Multiple Myeloma
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant Research Support: Amgen, Actinuum, Celgene, Johnson & Johnson, Takeda; Advisory Board: Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz Pharmaceuticals, Takeda, Novartis, Kite Pharma, Spectrum Pharmaceuticals.
Sonata Jodele, MD
Research Professor of Pediatrics
Division of Bone Marrow Transplantation and Immune Deficiency
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
Disclosures: Grant Research Support: NIH grant for TMA, drug provided for study subjects by Alexion at no charge (outside presented work); Consultant: One-time consultation for Magnolia Innovation and Arcus Medica; Other: Pending US patents. Travel support and payment for meeting presentation from Omeros.
The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PER, Physician Education Resource, LLC. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
Providership
This CME activity is jointly provided by The Medical College of Wisconsin and PER, Physician Education Resource, LLC.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.